Researchers lead by Dr. Teh, Bin Tean found that ccRCC tumor cells that had developed a resistance to Sunitinib had increased secretion of the protein interleukin-8 (IL-8). Administering Sunitinib and IL-8 neutralizing antibodies re-sensitized tumors to sunitinib treatment. Researchers also found that IL-8 may serve as a useful biomarker to predict patients' response to sunitinib treatment.
Interestingly, another study from same group of Teh’s laboratory, looked into exactly how sunitinib works. The study found that the treatment does not target tumor cells, but rather the tumor’s blood supply.
Researchers conclude that “it is now of critical importance to validate these findings in the clinical setting" and they hope that these insights will help to build upon recent advances to extend clinical benefits to more patients with metastatic kidney cancer....
Interestingly, another study from same group of Teh’s laboratory, looked into exactly how sunitinib works. The study found that the treatment does not target tumor cells, but rather the tumor’s blood supply.
Researchers conclude that “it is now of critical importance to validate these findings in the clinical setting" and they hope that these insights will help to build upon recent advances to extend clinical benefits to more patients with metastatic kidney cancer....
No comments:
Post a Comment